Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPardis Noor Medical Imaging and Cancer Center
About this trial
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.
Eligibility criteria
Qualifiers
Confirmation of metastatic liver cancer via histological examination or a characteristic imaging profile on dynamic computed tomography (CT) scan or magnetic resonance imaging (MRI) without indications for surgical resection
Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1
Liver function categorized as Child-Pugh class A or B
Stable non-hepatic metastases, such as skeletal, pulmonary, or lymph node metastases
Disqualifiers
Active infection
Presence of severe comorbidities, such as hepatic encephalopathy, refractory ascites, and esophageal variceal bleeding
Prior liver resection
Previous TACE therapy received at other healthcare facilities
Trial design
Treatments tested in this trial
- Bevacizumab
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov